NeoGenomics plays an essential role in helping our Pharma partners through therapeutic development and approval, saving thousands of lives around the world in the process.
NeoGenomics is a network of CAP-accredited, CLIA-certified labs and is the largest oncology specialty biomarker assay-focused contract research organization. With a well-established global footprint, we can ensure site-by-site consistency across large multi-national clinical trials. These clinical trials have the potential to save the lives of the patients who participate and can lead to breakthrough therapies that save many more lives in the years to come.
Our Pharma clients benefit from the most informative, state-of-the-art molecular technology, ranging from whole exome sequencing, whole transcriptome sequencing, HLA typing, and the proprietary MultiOmyx™ high-order multiplexing methodology.
NeoGenomics Pharma Services works side by side with you – our pharmaceutical and biotech partners – to seek out the answers to cancer’s never-ending questions and deliver hope and better futures for those living with cancer.
NeoGenomics Pharma Services has an international presence. Opening its first European laboratory in Rolle, Switzerland, just outside Geneva, in October 2017, and China in 2021.
Fort Myers, FL 33912
Aliso Viejo, CA 92656
Riverdale, GA 30345
Carlsbad, CA 92008
Mokena, IL 60448
Houston, TX 77085
Z.A. La Piece/Route de l’Etraz 1
Batiment A5, 2nd Floor
Rolle, Switzerland, 1180
San Diego, CA 92121
Huguan Industrial Park, Suzhou New District
Suzhou Shi, Jiangsu Sheng 215600
Temple Terrace, FL 33637
Our customers include 19 of the top 20 oncology biopharma companies
Transfer and validate biomarker assays: Our dedicated team of experts will work with you to understand your challenges and suggest potential solutions, including clinical trial support and post clinical trial services.
The technologies offered at NeoGenomics had advantages over other CRO's we explored including the ability to obtain high quality RNAseq data from challenging starting materials such as FFPE and the ability of MultiOmyx® technology to measure multiple markers within a single FFPE slide while avoiding the issue of spectral overlap that arise from more traditional immunofluorescence approaches.
The NeoGenomics team has the technical expertise to develop and qualify novel multiplexing assays to support preclinical and clinical testing of samples from clinical studies to the highest standards. The technical team has been very collaborative and interactive with the IAVI team and paid close attention to the client's requirements.
Contact Us To Get Started!
Work with us – your premier oncology partner – to optimize cancer care for patients